对人类癌症中二硫键下垂相关基因进行系统评估，并探讨二硫键下垂在癌症药物敏感性中的预测作用。我们开发了一个评分水平模型，使用 TCGA 数据量化 33 种人类癌症的二硫下垂水平。从人类蛋白质图谱中检测并检索人类癌细胞和组织中二硫键相关基因的 mRNA 表达和蛋白质水平。通过多组学生物信息学分析来评估二硫下垂相关基因特征以及二硫下垂对癌症免疫微环境和耐药性的影响。三十种癌症在正常和肿瘤样本之间显示出与二硫下垂相关基因的表达水平显着不同。肺癌和肝细胞癌中二硫下垂相关基因的mRNA表达量和蛋白水平与TCGA数据库一致。我们还发现，二硫下垂评分表达水平的改变通常与患者预后相关，并且二硫下垂相关基因的高表达与不同癌症类型的耐药性相关。我们的研究阐明了多种癌症类型中二硫下垂的特征，并强调了其作为药物反应的预测生物标志物的潜在价值，这可以为进一步研究二硫下垂的预后和治疗潜力铺平道路。

To get a systematic assessment of disulfidptosis-related genes across human cancers and explore the predictive role of disulfidptosis in cancer drug sensitivity. We developed a score-level model to quantify the level of disulfidptosis in 33 human cancers using TCGA data. The mRNA expression and protein levels of disulfidptosis-related genes in human cancer cells and tissues were detected and retrieved from the Human Protein Atlas. Multiomics bioinformatic analyses were performed to evaluate disulfidptosis-related gene characteristics as well as the effect of disulfidptosis on the cancer immune microenvironment and drug resistance. Thirty cancers showed significantly different expression levels of disulfidptosis-related genes between normal and tumor samples. The mRNA expression and protein level of disulfidptosis-related genes were consistent with TCGA databases in lung cancer and hepatocellular carcinoma. We also found that altered levels of the disulfidptosis score expression were usually related to patient prognosis, and high expression of disulfidptosis-related genes was associated with drug resistance in different cancer types. Our study illustrates the characterization of disulfidptosis in multiple cancer types and highlights its potential value as a predictive biomarker of drug response, which can pave the way for further investigation of the prognostic and therapeutic potential of disulfidptosis.